A milestone celebration of diversity, innovation, and global impact made in Australia
Posted: 11 February 2025 2025 Women in Leadership Awardees announced On the 10th UN International Day of Women and Girls in STEM, the 2025 BioMelbourne Network Women in Leadership Awards marked an extraordinary milestone: ten years of recognising…
BioMelbourne Network Women in Leadership Awards celebrate diversity, innovation and global impact made in Australia
Posted: 11 February 2025 Making 10 years of celebrating leadership, the BioMelbourne Network Women in Leadership Awards recognise the contribution of three inspiring women advancing global healthcare innovation. BioMelbourne Network proudly announces the recipients of its prestigious 2025…
New “all-tablet” treatment advance for common form of leukaemia
Posted: 10 February 2025 An international study published today in the New England Journal of Medicine provides hope for chronic lymphocytic leukaemia (CLL) patients with a new all-tablet treatment showing impressive results. The AMPLIFY clinical trial included over 800 never-before-treated…
Type C Meeting granted by FDA for Phelan-McDermid syndrome
Posted: 10 February 2025 Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted a Type C Meeting to discuss the primary efficacy endpoints in Neuren’s planned pivotal Phase 3 clinical trial…
INOVIQ ESTABLISHES MEDICAL AND SCIENTIFIC ADVISORY BOARD
Posted: 10 February 2025 INOVIQ Limited (ASX:IIQ) is pleased to announce the establishment of its Medical and Scientific Advisory Board (MSAB). The MSAB will provide world-class research expertise, clinical insight and strategic advice focusing on liquid biopsy diagnostics…
“East to West” cellular immunotherapy strategy prioritized
Posted: 10 February 2025 AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”) is pleased to announce the acceleration of its “East to West” cellular immunotherapy growth strategy with the execution of two further non-binding term sheets to in-license clinical…
High resolution retinal maps aid disease diagnoses
Posted: 6 February 2025 Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes, dementia and multiple sclerosis.…
Cell Bauhaus receives $3 million grant for digital twin research into cell behaviour
Posted: 6 February 2025 University of Melbourne affiliated startup Cell Bauhaus has received a $3 million grant from the Gates Foundation (formerly the Bill & Melinda Gates Foundation) to continue their work utilising digital twins to investigate how…
Australia’s TGA Approves Registration of CSL’s ANDEMBRY for the Prevention of Recurrent Hereditary Angioedema Attacks
Posted: 5 February 2025 Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the Australian Therapeutic Goods Administration (TGA) has approved the registration of ANDEMBRY® (garadacimab) for routine prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 12…
Amplia completes recruitment of ACCENT Trial
Posted: 5 February 2025 Amplia has today announced that it has completed the planned enrolment of the ACCENT Phase 2a clinical trial. The two-stage ACCENT trial is investigating the use of the Company’s best-in-class FAK inhibitor narmafotinib in…
Investing In Medtech So Patients Can Breathe Easier
Posted: 5 February 2025 The Allan Labor Government is backing local medical technology startup Diag-Nose Medical to develop new treatments for chronic respiratory disorders, which has the potential to help millions of people worldwide. Minister for Economic Growth and…
Optiscan kicks off GI study in Germany with first imaging prototype
Posted: 5 February 2025 Optiscan has been featured in Stockhead, The Australian, and 11 News Corp mastheads following the announcement of its pre-clinical gastrointestinal (GI) study in Germany. The piece explores how Optiscan’s first flexible GI imaging prototype…
